A Phase 3 interventional study of TAP-144-SR(6M) and TAP-144-SR(3M) in Premenopausal Breast Cancer, sponsored by Takeda. Completed at 15 sites in Japan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-11-26.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 266 studies in Breast Neoplasms with a site in Japan — 51 open to participants now, 113 under way, 56 of them phase 3. Breast Neoplasms · Japan.
Among the 266 studies in Breast Neoplasms with a site in Japan, this one is the 153rd largest by enrollment of the 248 interventional ones that give a count, is one of 10 that started in 2012, is one of 112 in phase 3, and was the 72nd registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →51 of the 266 studies in Breast Neoplasms with a site in Japan are open now. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Japan, United States, Belgium and 5 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Japan, Australia
Ages 18+
Stemline Therapeutics, Inc. · Sites in Japan
Ages 18+
Novartis Pharmaceuticals · Sites in Japan, United States, Australia and 1 more country
Ages 18+
Novartis Pharmaceuticals · Sites in Japan, United States, Canada and 6 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 20 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
266 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 69 · Phase 2 83 · Phase 3 114 · Phase 4 1
First in 1996; this study’s year is marked. 10 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 167 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 281 across the 248 interventional studies, 312 across the 17 observational. Of the 152 that completed or were terminated, 84 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
216 of 266 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Takeda has 9 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
21 of the studies in Breast Neoplasms with a site in Japan that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05909397Phase 3PfizerVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | 2026-12-30 |
| NCT05774951Phase 3AstraZenecaA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | 2027-04-20 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT05894239Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | 2027-05-03 |
| NCT06312176Phase 3Merck Sharp & Dohme LLCA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | 2027-07-11 |
Add all 21 to your calendar (.ics) → With an account.
Among the 266 studies in Breast Neoplasms with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hormone dynamics, pharmacokinetics, safety, and efficacy of TAP-144-SR(6M) will be evaluated against TAP-144-SR(3M) in postoperative and hormone therapy-naïve patients with premenopausal breast cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The participant meets the following criteria of hepatic, renal and bone marrow functions on the laboratory test results at screening:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 96 weeks.
Drug: TAP-144-SR(6M)
TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 96 weeks.
Drug: TAP-144-SR(3M)
Percentage of Participants With Suppressive Effect of Serum Estradiol (E2) to Menopausal Level (=<30 pg/mL) From Week 4 Through Week 48
Comparison of both the treatment groups was done by assessing the suppressive effect on serum E2 concentration maintained at menopausal level (=\<30pg/mL). Suppression rate was calculated as proportion of participants maintained at menopausal level.
Time frame: Week 4 up to Week 48
Concentration of Serum E2
The measure indicates serum E2 concentration at baseline and post-baseline time points.
Time frame: Baseline, Hour (hr) 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673
Concentration of Serum Luteinizing Hormone (LH)
This measure indicates serum LH concentration at baseline and post-baseline time points. It was measured in milli-international units per milliliter (mIU/mL).
Time frame: Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673
Concentration of Follicle Stimulating Hormone (FSH)
This measure indicates serum FSH concentration at baseline and post-baseline time points.
Time frame: Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673
Disease Free Survival (DFS) Rate at Week 96
DFS is defined as time from randomization to earliest day of onset the events, recurrence \[including recurrence in the ipsilateral breast\], secondary cancer \[including breast cancer in the contralateral breast\] and death. DFS at Week 96 was defined as the percentage, calculated with Kaplan-Meier method, of participants did not experience any events at Week 96 since the randomization.
Time frame: Week 96
Distant Disease Free Survival (DDFS) Rate at Week 96
DDFS is defined as time from randomization to earliest day of onset the events, distant recurrence, secondary cancer \[including breast cancer in the contralateral breast\] and death. DDFS at week 96 was defined as the percentage calculated with Kaplan-Meier method, of participants did not experience any events at week 96 since the randomization.
Time frame: Week 96
Serum Unchanged TAP-144 Level
This measure indicates the unchanged TAP-144 level in serum.
Time frame: Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309 and 337
QT Interval Measured by 12-lead Electrocardiogram (ECG)
12-lead electrocardiography measurement was performed in supine position after 5 minutes at rest. Each measurement was recorded continuously for 10 seconds at the recording speed of 25 millimeter/second (mm/second).
Time frame: Baseline, Hour 1, 3, 6 on Day 1, Day 29, 85, 169 and 337
Participants took part in the study at 21 investigative sites in Japan from April 2012 to December 2014.
| Milestone | TAP-144-SR (6M) | TAP-144-SR (3M) |
|---|---|---|
| Started | 83 | 84 |
| Completed | 75 | 75 |
| Not completed | 8 | 9 |
| Withdrew: Adverse event | 4 | 5 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Recurrence | 1 | 1 |
| Withdrew: Discovery of secondary cancer | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 |
Comparison of both the treatment groups was done by assessing the suppressive effect on serum E2 concentration maintained at menopausal level (=\<30pg/mL). Suppression rate was calculated as proportion of participants maintained at menopausal level.
| percentage of participants | TAP-144-SR (6M) | TAP-144-SR (3M) |
|---|---|---|
| Percentage of Participants With Suppressive Effect of Serum Estradiol (E2) to Menopausal Level (=<30 pg/mL) From Week 4 Through Week 48 | 97.6 (91.565 to 99.707) | 96.4 (89.916 to 99.257) |
The measure indicates serum E2 concentration at baseline and post-baseline time points.
| pg/mL | TAP-144-SR (6M) | TAP-144-SR (3M) |
|---|---|---|
| Baseline [N=83;84] | 95 (0 to 652) | 99 (0 to 533) |
| Day1 (1hr) [N=82;84] | 94.5 (0 to 616) | 110.5 (0 to 518) |
| Day1 (3hr) [N=24;21] | 102.0 (0 to 602) | 64.0 (15 to 404) |
| Day1 (6hr) [N=24;21] | 153.5 (0 to 681) | 99.0 (16 to 533) |
| Day2 [N=83;84] | 146.0 (0 to 693) | 115.5 (0 to 333) |
| Day3 [N=83;84] | 100.0 (0 to 417) | 87.5 (0 to 311) |
| Day4 [N=83;84] | 108.0 (0 to 543) | 110.0 (0 to 453) |
| Week 1 (Day8) [N=83;84] | 56.0 (0 to 904) | 112.0 (0 to 981) |
| Week 2 (Day15) [N=83;84] | 13.0 (0 to 866) | 0.0 (0 to 1220) |
| Week 3 (Day22) [N=83;84] | 0.0 (0 to 196) | 0.0 (0 to 722) |
| Week 4 (Day29) [N=83;84] | 0.0 (0 to 14) | 0.0 (0 to 50) |
| Week 8 (Day57) [N=83;84] | 0.0 (0 to 12) | 0.0 (0 to 158) |
| Week 12 (Day85) [N=83;83] | 0.0 (0 to 12) | 0.0 (0 to 11) |
| Week 16 (Day113) [N=82;82] | 0.0 (0 to 69) | 0.0 (0 to 16) |
| Week 20 (Day141) [N=81;82] | 0.0 (0 to 15) | 0.0 (0 to 15) |
| Week 24 (Day169) [N=80;81] | 0.0 (0 to 27) | 0.0 (0 to 20) |
| Week 25 (Day176) [N=79;80] | 0.0 (0 to 18) | 0.0 (0 to 15) |
| Week 26 (Day183) [N=79;80] | 0.0 (0 to 14) | 0.0 (0 to 19) |
| Week 28 (Day197) [N=75;77] | 0.0 (0 to 14) | 0.0 (0 to 16) |
| Week 32 (Day225) [N=78;80] | 0.0 (0 to 17) | 0.0 (0 to 18) |
| Week 36 (Day253) [N=79;80] | 0.0 (0 to 18) | 0.0 (0 to 17) |
| Week 40 (Day281) [N=78;80] | 0.0 (0 to 184) | 0.0 (0 to 12) |
| Week 44 (Day309) [N=77;80] | 0.0 (0 to 16) | 0.0 (0 to 15) |
| Week 48 (Day337) [N=77;80] | 0.0 (0 to 15) | 0.0 (0 to 19) |
| Week 60 (Day421) [N=77;79] | 0.0 (0 to 25) | 0.0 (0 to 21) |
| Week 72 (Day505) [N=77;78] | 0.0 (0 to 14) | 0.0 (0 to 18) |
| Week 84 (Day589) [N=76;77] | 0.0 (0 to 15) | 0.0 (0 to 14) |
| Week 96 (Day673) [N=75;75] | 0.0 (0 to 12) | 0.0 (0 to 24) |
This measure indicates serum LH concentration at baseline and post-baseline time points. It was measured in milli-international units per milliliter (mIU/mL).
| mIU/mL | TAP-144-SR (6M) | TAP-144-SR (3M) |
|---|---|---|
| Baseline [N=83;84] | 4.250 (0.69 to 65.33) | 4.490 (0.77 to 40.17) |
| Day1 (1hr) [N=82;84] | 27.730 (8.12 to 250.00) | 30.585 (2.78 to 207.30) |
| Day1 (3hr) [N=24;21] | 88.020 (24.64 to 250.00) | 63.260 (12.00 to 153.60) |
| Day1 (6hr) [N=24;21] | 64.750 (32.54 to 198.90) | 61.210 (12.68 to 106.10) |
| Day2 [N=83;84] | 14.990 (3.22 to 90.63) | 19.755 (1.84 to 154.30) |
| Day3 [N=83;84] | 7.310 (1.28 to 27.86) | 10.500 (1.73 to 59.52) |
| Day4 [N=83;84] | 5.830 (1.13 to 41.16) | 9.375 (1.63 to 56.11) |
| Week 1 (Day8) [N=83;84] | 3.190 (0.75 to 25.08) | 4.475 (1.18 to 29.68) |
| Week 2 (Day15) [N=83;84] | 2.460 (0.76 to 10.56) | 1.990 (0.75 to 9.65) |
| Week 3 (Day22) [N=83;84] | 1.020 (0.24 to 4.39) | 1.085 (0.38 to 5.35) |
| Week 4 (Day29) [N=83;84] | 0.540 (0.16 to 1.85) | 0.845 (0.33 to 2.73) |
| Week 8 (Day57) [N=83;84] | 0.270 (0.00 to 1.15) | 0.570 (0.00 to 5.17) |
| Week 12 (Day85) [N=83;83] | 0.220 (0.00 to 1.84) | 0.520 (0.00 to 2.70) |
| Week 16 (Day113) [N=82;82] | 0.245 (0.00 to 7.08) | 0.430 (0.00 to 1.42) |
| Week 20 (Day141) [N=81;82] | 0.240 (0.00 to 2.26) | 0.405 (0.00 to 2.93) |
| Week 24 (Day169) [N=80;81] | 0.290 (0.00 to 8.01) | 0.460 (0.11 to 2.96) |
| Week 25 (Day176) [N=79;80] | 0.450 (0.00 to 7.92) | 0.455 (0.15 to 1.47) |
| Week 26 (Day183) [N=79;80] | 0.410 (0.12 to 2.46) | 0.405 (0.14 to 1.70) |
| Week 28 (Day197) [N=75;77] | 0.270 (0.11 to 0.95) | 0.410 (0.11 to 1.68) |
| Week 32 (Day225) [N=78;80] | 0.280 (0.00 to 1.31) | 0.440 (0.14 to 2.45) |
| Week 36 (Day253) [N=79;80] | 0.250 (0.00 to 2.02) | 0.395 (0.11 to 2.01) |
| Week 40 (Day281) [N=78;80] | 0.240 (0.00 to 2.05) | 0.390 (0.12 to 1.75) |
| Week 44 (Day309) [N=77;80] | 0.250 (0.00 to 2.67) | 0.385 (0.00 to 2.14) |
| Week 48 (Day337) [N=77;80] | 0.250 (0.00 to 2.12) | 0.415 (0.11 to 1.30) |
| Week 60 (Day421) [N=77;79] | 0.250 (0.00 to 1.52) | 0.440 (0.00 to 2.57) |
| Week 72 (Day505) [N=77;78] | 0.260 (0.00 to 1.24) | 0.420 (0.00 to 1.91) |
| Week 84 (Day589) [N=76;77] | 0.230 (0.00 to 1.30) | 0.410 (0.00 to 1.34) |
| Week 96 (Day673) [N=75;75] | 0.210 (0.00 to 1.48) | 0.360 (0.00 to 1.63) |
This measure indicates serum FSH concentration at baseline and post-baseline time points.
| mIU/mL | TAP-144-SR (6M) | TAP-144-SR (3M) |
|---|---|---|
| Baseline [N=83;84] | 5.070 (1.97 to 57.33) | 5.605 (2.03 to 66.13) |
| Day1 (1hr) [N=82;84] | 9.520 (4.01 to 102.42) | 10.000 (4.02 to 99.71) |
| Day1 (3hr) [N=24;21] | 23.325 (8.39 to 110.28) | 19.950 (10.06 to 74.66) |
| Day1 (6hr) [N=24;21] | 27.460 (11.19 to 147.78) | 25.340 (10.85 to 107.69) |
| Day2 [N=83;84] | 10.080 (2.78 to 93.70) | 12.515 (3.23 to 115.42) |
| Day3 [N=83;84] | 6.180 (2.86 to 45.56) | 6.780 (3.09 to 55.25) |
| Day4 [N=83;84] | 6.100 (2.84 to 37.79) | 5.585 (2.75 to 36.28) |
| Week 1 (Day8) [N=83;84] | 3.920 (0.99 to 14.09) | 3.035 (1.19 to 11.62) |
| Week 2 (Day15) [N=83;84] | 1.820 (0.58 to 7.49) | 1.705 (0.47 to 4.63) |
| Week 3 (Day22) [N=83;84] | 1.220 (0.49 to 3.22) | 1.570 (0.49 to 4.68) |
| Week 4 (Day29) [N=83;84] | 1.200 (0.39 to 2.48) | 2.015 (0.68 to 7.37) |
| Week 8 (Day57) [N=83;84] | 1.390 (0.36 to 5.15) | 2.345 (0.87 to 7.75) |
| Week 12 (Day85) [N=83;83] | 1.490 (0.37 to 5.72) | 2.240 (0.76 to 7.06) |
| Week 16 (Day113) [N=82;82] | 1.635 (0.59 to 11.04) | 1.830 (0.69 to 4.82) |
| Week 20 (Day141) [N=81;82] | 1.780 (0.53 to 7.28) | 1.905 (0.87 to 8.76) |
| Week 24 (Day169) [N=80;81] | 2.060 (0.42 to 6.24) | 2.000 (0.59 to 6.52) |
| Week 25 (Day176) [N=79;80] | 1.940 (0.71 to 5.22) | 1.600 (0.51 to 4.25) |
| Week 26 (Day183) [N=79;80] | 1.560 (0.53 to 3.40) | 1.700 (0.64 to 3.71) |
| Week 28 (Day197) [N=75;77] | 1.310 (0.52 to 2.81) | 1.690 (0.59 to 5.91) |
| Week 32 (Day225) [N=78;80] | 1.595 (0.52 to 4.81) | 1.980 (0.57 to 4.69) |
| Week 36 (Day253) [N=79;80] | 1.660 (0.73 to 6.12) | 2.035 (0.67 to 5.49) |
| Week 40 (Day281) [N=78;80] | 1.735 (0.75 to 4.09) | 1.710 (0.71 to 7.62) |
| Week 44 (Day309) [N=77;80] | 1.930 (0.72 to 5.01) | 1.825 (0.70 to 6.39) |
| Week 48 (Day337) [N=77;80] | 1.920 (0.69 to 8.37) | 1.885 (0.72 to 4.09) |
| Week 60 (Day421) [N=77;79] | 1.530 (0.74 to 4.71) | 1.910 (0.64 to 4.75) |
| Week 72 (Day505) [N=77;78] | 1.730 (0.92 to 5.89) | 1.920 (0.63 to 4.30) |
| Week 84 (Day589) [N=76;77] | 1.500 (0.77 to 3.23) | 1.840 (0.66 to 3.74) |
| Week 96 (Day673) [N=75;75] | 1.620 (0.76 to 4.57) | 1.740 (0.59 to 7.01) |
DFS is defined as time from randomization to earliest day of onset the events, recurrence \[including recurrence in the ipsilateral breast\], secondary cancer \[including breast cancer in the contralateral breast\] and death. DFS at Week 96 was defined as the percentage, calculated with Kaplan-Meier method, of participants did not experience any events at Week 96 since the randomization.
| percentage of participants | TAP-144-SR (6M) | TAP-144-SR (3M) |
|---|---|---|
| Disease Free Survival (DFS) Rate at Week 96 | 97.3 | 97.5 |
DDFS is defined as time from randomization to earliest day of onset the events, distant recurrence, secondary cancer \[including breast cancer in the contralateral breast\] and death. DDFS at week 96 was defined as the percentage calculated with Kaplan-Meier method, of participants did not experience any events at week 96 since the randomization.
| percentage of participants | TAP-144-SR (6M) | TAP-144-SR (3M) |
|---|---|---|
| Distant Disease Free Survival (DDFS) Rate at Week 96 | 98.5 | 98.8 |
This measure indicates the unchanged TAP-144 level in serum.
| nanogram per deciliter (ng/dL) | TAP-144-SR (6M) | TAP-144-SR (3M) |
|---|---|---|
| Baseline [N=83;84] | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| Day1 (1hr) [N=82;84] | 5.293 ± 1.0684 | 28.45 ± 9.7398 |
| Day1 (3hr) [N=24;19] | 2.538 ± 0.46023 | 20.27 ± 3.9535 |
| Day1 (6hr) [N=24;21] | 1.039 ± 0.23264 | 8.037 ± 1.7408 |
| Day2 [N=83;84] | 0.1401 ± 0.066137 | 0.4749 ± 0.17801 |
| Day3 [N=83;84] | 0.02889 ± 0.026108 | 0.2492 ± 0.097054 |
| Day4 [N=83;84] | 0.02380 ± 0.022645 | 0.2273 ± 0.080794 |
| Week 1 (Day8) [N=82;83] | 0.09115 ± 0.22637 | 0.1050 ± 0.049062 |
| Week 2 (Day15) [N=82;84] | 0.3702 ± 0.25134 | 0.08867 ± 0.077142 |
| Week 3 (Day22) [N=83;84] | 0.7285 ± 0.35639 | 0.06471 ± 0.092279 |
| Week 4 (Day29) [N=83;83] | 0.3442 ± 0.19814 | 0.04971 ± 0.032917 |
| Week 8 (Day57) [N=83;83] | 0.1146 ± 0.053068 | 0.04744 ± 0.032379 |
| Week 12 (Day85) [N=83;83] | 0.08051 ± 0.041881 | 0.06028 ± 0.031104 |
| Week 16 (Day113) [N=82;82] | 0.05775 ± 0.037098 | 0.09347 ± 0.077284 |
| Week 20 (Day141) [N=81;82] | 0.03941 ± 0.037082 | 0.07165 ± 0.062739 |
| Week 24 (Day169) [N=80;81] | 0.02931 ± 0.019785 | 0.07634 ± 0.064118 |
| Week 25 (Day176) [N=79;80] | 0.1128 ± 0.16751 | 0.1583 ± 0.089299 |
| Week 26 (Day183) [N=79;80] | 0.3327 ± 0.36474 | 0.1109 ± 0.065133 |
| Week 28 (Day197) [N=80;80] | 0.4687 ± 0.36083 | 0.08468 ± 0.040820 |
| Week 32 (Day225) [N=78;80] | 0.1377 ± 0.093340 | 0.06881 ± 0.037607 |
| Week 36 (Day253) [N=79;80] | 0.08521 ± 0.040324 | 0.06259 ± 0.036687 |
| Week 40 (Day281) [N=79;80] | 0.06073 ± 0.032232 | 0.08163 ± 0.031631 |
| Week 44 (Day309) [N=77;80] | 0.4339 ± 0.026552 | 0.06479 ± 0.028540 |
| Week 48 (Day337) [N=77;80] | 0.02957 ± 0.017147 | 0.06313 ± 0.032149 |
12-lead electrocardiography measurement was performed in supine position after 5 minutes at rest. Each measurement was recorded continuously for 10 seconds at the recording speed of 25 millimeter/second (mm/second).
| millisecond (msec) | TAP-144-SR (6M) | TAP-144-SR (3M) |
|---|---|---|
| Baseline [N=83;84] | 421.5 ± 16.05 | 420.9 ± 16.53 |
| Day1 (1hr) [N=83;84] | 417.8 ± 15.37 | 417.1 ± 17.83 |
| Day1 (3hr) [N=24;21] | 416.8 ± 11.34 | 423.7 ± 18.90 |
| Day1 (6hr) [N=24;21] | 415.8 ± 18.68 | 424.1 ± 13.76 |
| Week 4 (Day29) [N=83;84] | 431.2 ± 19.30 | 432.3 ± 16.90 |
| Week 12 (Day85) [N=83;84] | 433.3 ± 19.44 | 432.3 ± 20.01 |
| Week 24 (Day169) [N=81;82] | 431.0 ± 21.22 | 429.0 ± 20.28 |
| Week 48 (Day337) [N=77;80] | 430.0 ± 17.31 | 431.4 ± 18.89 |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TAP-144-SR (6M) | — | 6/83 (7.2%) | 82/83 (98.8%) |
| TAP-144-SR (3M) | — | 7/84 (8.3%) | 82/84 (97.6%) |
| Event | TAP-144-SR (6M) | TAP-144-SR (3M) |
|---|---|---|
| Eyelid ptosisEye disorders | 1/83 | 0/84 |
| Anal fistulaGastrointestinal disorders | 1/83 | 0/84 |
| GastroenteritisInfections and infestations | 1/83 | 0/84 |
| Infectious mononucleosisInfections and infestations | 1/83 | 0/84 |
| Multiple sclerosisNervous system disorders | 1/83 | 0/84 |
| VIIth nerve paralysisNervous system disorders | 1/83 | 0/84 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 1/83 | 1/84 |
| CholelithiasisHepatobiliary disorders | 0/83 | 1/84 |
| SinusitisInfections and infestations | 0/83 | 1/84 |
| Occult blood positiveInvestigations | 0/83 | 1/84 |
| Event | TAP-144-SR (6M) | TAP-144-SR (3M) |
|---|---|---|
| Hot flushVascular disorders | 43/83 | 48/84 |
| NasopharyngitisInfections and infestations | 47/83 | 42/84 |
| Radiation skin injuryInjury, poisoning and procedural complications | 31/83 | 39/84 |
| Injection site indurationGeneral disorders | 36/83 | 33/84 |
| White blood cell count decreasedInvestigations | 27/83 | 19/84 |
| Injection site painGeneral disorders | 24/83 | 26/84 |
| HeadacheNervous system disorders | 21/83 | 19/84 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 18/83 | 20/84 |
| ConstipationGastrointestinal disorders | 13/83 | 2/84 |
| MalaiseGeneral disorders | 13/83 | 13/84 |
Full analysis set (FAS) included all randomized participants who had received at least a single dose of study treatment.
| Age, Continuous(years) | TAP-144-SR (6M) | TAP-144-SR (3M) | Total |
|---|---|---|---|
| Mean | 44.2 ± 4.90 | 44.0 ± 5.18 | 44.1 ± 5.03 |
| Age, Customized(participants) | TAP-144-SR (6M) | TAP-144-SR (3M) | Total |
|---|---|---|---|
| Less than (<) 40 years | 13 | 12 | 25 |
| Greater than equal to (>=) 40 to <45 years | 29 | 30 | 59 |
| >=45 years | 41 | 42 | 83 |
| Sex: Female, Male(Participants) | TAP-144-SR (6M) | TAP-144-SR (3M) | Total |
|---|---|---|---|
| Female | 83 | 84 | 167 |
| Male | 0 | 0 | 0 |
| Height(centimeter (cm)) | TAP-144-SR (6M) | TAP-144-SR (3M) | Total |
|---|---|---|---|
| Mean | 159.3 ± 5.11 | 158.1 ± 5.00 | 158.7 ± 5.08 |
| Height, Customized(participants) | TAP-144-SR (6M) | TAP-144-SR (3M) | Total |
|---|---|---|---|
| <150 cm | 2 | 3 | 5 |
| >=150 to <160 cm | 40 | 53 | 93 |
| >=160 cm | 41 | 28 | 69 |
| Weight(kilogram (kg)) | TAP-144-SR (6M) | TAP-144-SR (3M) | Total |
|---|---|---|---|
| Mean | 54.48 ± 7.670 | 53.57 ± 7.498 | 54.02 ± 7.574 |
| Weight, Customized(participants) | TAP-144-SR (6M) | TAP-144-SR (3M) | Total |
|---|---|---|---|
| <50 kg | 25 | 29 | 54 |
| >=50 to <60 kg | 40 | 40 | 80 |
| >=60 kg | 18 | 15 | 33 |
| Body Mass Index (BMI)(kilogram per square meter (kg/m^2)) | TAP-144-SR (6M) | TAP-144-SR (3M) | Total |
|---|---|---|---|
| Mean | 21.50 ± 3.042 | 21.45 ± 2.902 | 21.48 ± 2.964 |
28 further baseline measures are reported on the registry.
The record gives a start of Apr 2012, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leuprolide